Volume 143, Issue 2, Pages (August 2012)

Slides:



Advertisements
Similar presentations
Flavia D. Mendes, Ayako Suzuki, Schuyler O. Sanderson, Keith D
Advertisements

Incorrect Calculation and Inappropriate Interpretation: Accuracy of International Guidelines for Identifying Significant Fibrosis in e Antigen–Negative.
Abhishek Chauhan, David H. Adams  Gastroenterology 
Les Lang  Gastroenterology  Volume 133, Issue 1, (July 2007)
Volume 137, Issue 4, Pages (October 2009)
Volume 154, Issue 4, Pages e6 (March 2018)
Volume 131, Issue 2, Pages (August 2006)
Les Lang  Gastroenterology  Volume 133, Issue 1, (July 2007)
Covering the Cover Gastroenterology
Volume 133, Issue 1, Pages (July 2007)
Evaluation and Management of End-Stage Liver Disease in Children
Lost in Inflammation: The Functional Conversion of Regulatory T Cells in Acute Hepatitis A Virus Infection  Tobias Boettler, Robert Thimme  Gastroenterology 
Volume 138, Issue 5, Pages e2 (May 2010)
Volume 132, Issue 7, Pages (June 2007)
Ira J. Fox, Stephen C. Strom  Gastroenterology 
Volume 149, Issue 2, Pages (August 2015)
Volume 145, Issue 5, Pages (November 2013)
Volume 141, Issue 4, Pages e2 (October 2011)
Volume 137, Issue 4, Pages e5 (October 2009)
Volume 154, Issue 5, Pages (April 2018)
Volume 135, Issue 4, Pages (October 2008)
Issue Highlights Clinical Gastroenterology and Hepatology
Volume 137, Issue 2, Pages (August 2009)
Volume 141, Issue 2, Pages e1 (August 2011)
A Double-Blind Randomized Placebo-Controlled Trial of Orlistat for the Treatment of Nonalcoholic Fatty Liver Disease  Shira Zelber–Sagi, Ada Kessler,
Volume 153, Issue 5, Pages e2 (November 2017)
Abstracts from Around the World
Volume 134, Issue 4, Pages e8 (April 2008)
Volume 149, Issue 2, Pages (August 2015)
Volume 150, Issue 3, Pages e7 (March 2016)
Volume 140, Issue 1, Pages e3 (January 2011)
Noninvasive Assessment of Nonalcoholic Fatty Liver Disease in Obese or Overweight Patients  Sven M.A. Francque, An Verrijken, Ilse Mertens, Guy Hubens,
Cytokeratin 18 Fragment Levels as a Noninvasive Biomarker for Nonalcoholic Steatohepatitis in Bariatric Surgery Patients  Dima L. Diab, Lisa Yerian, Philip.
Volume 141, Issue 4, Pages e3 (October 2011)
Randomized Placebo-Controlled Trial of Ursodeoxycholic Acid With Vitamin E in Nonalcoholic Steatohepatitis  Jean–François Dufour, Carl M. Oneta, Jean–Jacques.
Volume 144, Issue 2, Pages (February 2013)
Volume 138, Issue 2, Pages e4 (February 2010)
Volume 140, Issue 4, Pages (April 2011)
Rohit Loomba, MD, MHSc  Clinical Gastroenterology and Hepatology 
Impact of New Hepatitis C Treatments in Different Regions of the World
Chan Wah Kheong, Nik Raihan Nik Mustapha, Sanjiv Mahadeva 
Efficient Early Drug Development for Ulcerative Colitis
Volume 140, Issue 7, Pages (June 2011)
Volume 150, Issue 2, Pages e9 (February 2016)
Volume 136, Issue 3, Pages e2 (March 2009)
Volume 150, Issue 3, Pages (March 2016)
Levels of Alanine Aminotransferase Confound Use of Transient Elastography to Diagnose Fibrosis in Patients With Chronic Hepatitis C Virus Infection  Elliot.
Volume 133, Issue 2, Pages (August 2007)
Correlation of FIBROSpect II With Histologic and Morphometric Evaluation of Liver Fibrosis in Chronic Hepatitis C  Keyur Patel, David R. Nelson, Don C.
Volume 127, Issue 3, Pages (September 2004)
Serum Activity of Macrophage-Derived Adenosine Deaminase 2 Is Associated With Liver Fibrosis in Nonalcoholic Fatty Liver Disease  Z. Gordon Jiang, Bynvant.
Volume 132, Issue 2, (February 2007)
Ashwin N. Ananthakrishnan, David Lieberman  Gastroenterology 
Covering the Cover Gastroenterology
Volume 150, Issue 5, Pages (May 2016)
Volume 140, Issue 6, Pages e2 (May 2011)
Alan Bonder, MD, Nezam H. Afdhal, MD 
Volume 135, Issue 6, Pages e2 (December 2008)
Volume 128, Issue 7, Pages (June 2005)
Volume 132, Issue 2, Pages (February 2007)
Volume 149, Issue 6, Pages (November 2015)
Volume 140, Issue 1, Pages (January 2011)
Volume 138, Issue 4, Pages e2 (April 2010)
Volume 142, Issue 6, Pages e4 (May 2012)
End-Stage Liver Disease in 2008: Finally a Glass Half Full
Serum markers detect the presence of liver fibrosis: A cohort study
Volume 132, Issue 7, Pages (June 2007)
Controversies in Liver Transplantation for Hepatitis C
Volume 135, Issue 5, Pages (November 2008)
Volume 138, Issue 2, Pages e4 (February 2010)
Presentation transcript:

Volume 143, Issue 2, Pages 448-458 (August 2012) Circulating Microparticles as Disease-Specific Biomarkers of Severity of Inflammation in Patients With Hepatitis C or Nonalcoholic Steatohepatitis  Miroslaw Kornek, Michael Lynch, Shruti H. Mehta, Michelle Lai, Mark Exley, Nezam H. Afdhal, Detlef Schuppan  Gastroenterology  Volume 143, Issue 2, Pages 448-458 (August 2012) DOI: 10.1053/j.gastro.2012.04.031 Copyright © 2012 AGA Institute Terms and Conditions

Figure 1 Comparison of S100-MP determinations from serum and plasma. FACS analysis revealed that both fresh plasma and stored serum samples can be used reliably to determine the levels of CD4+, CD14+, and iNKT MP. In agreement with previous reports, levels of platelet-derived MP (CD41+) were significantly decreased in serum.16 n, number of serum/plasma pairs; the bold number is the difference (in percent) between the means (not bold) of the measured MP population in serum vs plasma. Differences (percent in bold) between serum and plasma were calculated using the following formula: (mean plasma MP − mean serum MP)/mean serum MP. Gastroenterology 2012 143, 448-458DOI: (10.1053/j.gastro.2012.04.031) Copyright © 2012 AGA Institute Terms and Conditions

Figure 2 Gross overview/profile of the percentages of different S100-MP populations in patients with NAFL, CHC, and in healthy controls. (A) MP were isolated by differential centrifugation and analyzed by FACS as described in Materials and Methods. The overall P value for each MP population for the Kruskal–Wallis test was set at P < .0001 before assessing pairwise relationships by the post-hoc Dunn's multiple comparisons approach to compare the 3 study cohorts (CHC, NAFL/NASH, and healthy controls). (B) AUROC curves were created using those cut-off values that yielded the highest likelihood to differentiate between CHC, NAFL, and healthy controls (see also Supplementary Table 1). n, number of patients in each MP analysis. Occasional missing data points are due to limitation of serum. Ten additional patients with CHC for whom only CD4+ and CD8+ MP were available were included (see Table 1). Gastroenterology 2012 143, 448-458DOI: (10.1053/j.gastro.2012.04.031) Copyright © 2012 AGA Institute Terms and Conditions

Figure 3 MP levels in relation to normal and high ALT values and biopsy stage, and analysis CD14+ MP subsets. (A) MP levels in CHC or NAFL/NASH patients with normal ALT values (<40 IU/mL, numbers as indicated) or high ALT values (>100 IU/mL, numbers as indicated) as a surrogate of hepatic inflammation, and in comparison to S100-MP populations from healthy controls. The overall P value for each MP population for the Kruskal–Wallis test was set at P < .0001 before assessing pairwise relationships by the post-hoc Dunn's multiple comparisons approach to compare the 3 study cohorts (CHC, NAFL/NASH, and healthy controls). (B) Analysis of CD14+ S100-MP subpopulations in a representative cohort of NAFL/NASH patients. CD14+ CD16−: “classically activated” monocytes; CD14+CD16+: “nonclassically activated, inflammatory” monocytes, CD14+CD1c+: myeloid DCs. (C) In CHC CD4+ and CD8+, MP correlated well with fibrosis stage as we described previously in a smaller cohort3 (r = 0.63; P < .0001; r = 0.59; P = .0002, respectively). However, CD4+, CD8+, CD14+, and iNKT MP levels did not correlate with stage in NAFL/NASH (data not shown). Variations in numbers are due to limitation of serum. Gastroenterology 2012 143, 448-458DOI: (10.1053/j.gastro.2012.04.031) Copyright © 2012 AGA Institute Terms and Conditions

Figure 4 Correlations of circulating S100-MP with ALT. Correlations of CD4+, CD8+, CD14+, and iNKT S100-MP with patients' ALT values from blood samples used simultaneously for S100-MP isolation and ALT determination. (A) CHC, (B) NAFL/NASH. Correlations were calculated using the Pearson algorithm, with r values and P values shown in the lower right corner of each graph. Variations in numbers are due to limitation of serum. Gastroenterology 2012 143, 448-458DOI: (10.1053/j.gastro.2012.04.031) Copyright © 2012 AGA Institute Terms and Conditions

Figure 5 Correlations of circulating S100-MP with histological grade. S100-MP populations were isolated from the serum of CHC (A) or NAFL/NASH patients (B) with paired biopsies. Grading was done as detailed in Material and Methods. Correlations were calculated using Pearson's algorithm. Variations in numbers are due to limitation of serum. Gastroenterology 2012 143, 448-458DOI: (10.1053/j.gastro.2012.04.031) Copyright © 2012 AGA Institute Terms and Conditions

Figure 6 Correlations of circulating S100-MP populations with the NAS score and between MP populations. (A) Correlations of CD4+, CD8+, CD14+, CD15+, CD41+, and iNKT (Vα24/Vβ11 double-positive) S100-MP with the NAS score using the Pearson algorithm. (B) The strongest correlations between S100-MP subsets for each liver disease are shown. The strong correlation between CD14+ and iNKT S100-MP supports a tight functional link between these inflammatory cell types in NAFL/NASH. Variations in numbers are due to limitation of serum. Gastroenterology 2012 143, 448-458DOI: (10.1053/j.gastro.2012.04.031) Copyright © 2012 AGA Institute Terms and Conditions